SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (139)5/7/1997 1:38:00 AM
From: Miljenko Zuanic   of 675
 
Hi All!

Today, I have short conversation with CNSI CEO Mr. E. Gamzu.

It appears that we/I have few things mix-up. First related to Cerestat TBI/Stroke trials. In my response to Mr. Castro I was wrong in Cerestat dosing regimes for Stroke. Initial dose of 15 mg initial with 3mg/hr during 72 hr was in protocol for TBI.

For Stroke two dosing regimes: a) 5 mg initial with 0.75mg/hr during 12 hr and b) 3 mg initial with 0.5mg/hr during 12 hr.

BI is in full control of the both trials and is their decision for any interim results. For Stroke they are planing interim results in Jul/Aug and for TBI (3 months follow-on after therapy) in Sep.

Large difference in dosage between Stroke and TBI is related to difference in disease condition. Because Stroke/TBI trials are also blind for doctors there are no way to correlate some significant improvement at already treated patients with drug.

Antagonist for Neuregulin (cancer) is still at research stage and for the near future they are not planing partnership.

rhGGF2 for MS is near completion in preclinical and will enter clinical in 1998. They are looking for partner.

I didn't ask for CNS 5161 and EpoE-4.

Mr. Ganzu was very confident regards the pipeline products at CNSI, if that can help.

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News